Jd. Coplan et al., UNCOUPLING OF THE NORADRENERGIC-HYPOTHALAMIC-PITUITARY-ADRENAL AXIS IN PANIC DISORDER PATIENTS, Neuropsychopharmacology, 13(1), 1995, pp. 65-73
In this paper the authors examine the interrelationship of both the no
radrenergic (NA) system and the hypothalamic-pituitary-adrenal (HPA) a
xis and its implications for panic disorder (PD). Seventeen PD patient
s and 26 healthy volunteers were challenged orally 12 weeks apart with
the an-agonist clonidine (13 healthy volunteers and 12 patients repea
ted the challenge). Between challenges, PD patients were treated with
fluoxetine, with 10 of 12 improving at least moderately. Both during t
he acute phase of the illness and during the phase of pharmacological
improvement, patients demonstrated a greater percentage of reductions
of plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and plasma cortisol d
uring clonidine challenge. We used correlational matrices to examine t
he relationship between the NA system, as reflected by plasma MHPG, an
d the HPA axis, as reflected by plasma cortisol measures. Healthy volu
nteers exhibited multiple significant ''couplings'' between either bas
eline or maximal decrease (Delta(max)) of plasma MHPG, with either bas
eline or Delta(max) plasma cortisol measures both within the first and
second challenges anti between the first and second challenges. In co
ntrast, PD patients demonstrated ''uncoupling'' of the NA system and t
he HPA axis, with no significant correlations observed between either
baseline and/or maximal decrease (Delta(max)) measures of MHPG with th
e same cortisol measures for either the first or second challenge. The
same uncoupling was observed for NA/HPA correlations between the firs
t and second challenges. These data suggest that the hyperresponsivity
to clonidine in PD patients persists during fluoxetine treatment. The
y also raise the possibility that an uncoupling of the NA system and t
he HPA axis may be a feature of PD patients, even following clinically
significant improvement. The authors suggest suboptimal NA regulation
of the HPA axis in PD patients, with pathophysiological implications
particularly prominent during periods of stress-induced activation of
the two systems.